A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

CONCLUSIONS: Twice-weekly and thrice-weekly administration of ketamine at 0.5 mg/kg similarly maintained antidepressant efficacy over 15 days. PMID: 27056608 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27056608?dopt=Abstract

Source: The American Journal of Psychiatry - April 7, 2016 Category: Psychiatry Authors: Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L Tags: Am J Psychiatry Source Type: research